Trial · NCT01498445
Results by group22
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 22
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Ph I Study: Maximum Tolerated Dose (MTD) Dasatinib | Phase I - Dasatinib 100 mg + Decitabine 10 mg/m2 | NA | Milligrams | ||
| Ph I Study: Maximum Tolerated Dose (MTD) Dasatinib | Phase I - Dasatinib 100 mg + Decitabine 20 mg/m2 | NA | Milligrams | ||
| Ph I Study: Maximum Tolerated Dose (MTD) Dasatinib | Phase I - Dasatinib 140 mg + Decitabine 10 mg/m2 | 140 | Milligrams | ||
| Ph I Study: Maximum Tolerated Dose (MTD) Dasatinib | Phase I - Dasatinib 140 mg + Decitabine 20 mg/m2 | 140 | Milligrams | ||
| Number of Participants With Hematologic Responses During First 3 Months of Treatment | Phase I - Dasatinib 100 mg + Decitabine 10 mg/m2 | 3 | Participants | ||
| Number of Participants With Hematologic Responses During First 3 Months of Treatment | Phase I - Dasatinib 100 mg + Decitabine 20 mg/m2 | 1 | Participants | ||
| Number of Participants With Hematologic Responses During First 3 Months of Treatment | Phase I - Dasatinib 140 mg + Decitabine 10 mg/m2 | 5 | Participants | ||
| Number of Participants With Hematologic Responses During First 3 Months of Treatment | Phase I - Dasatinib 140 mg + Decitabine 20 mg/m2 | 4 | Participants | ||
| Number of Participants With Hematologic Responses During First 3 Months of Treatment | Phase II - Dasatinib 140 mg + Decitabine 10 mg/m2 | 3 | Participants | ||
| Number of Participants With Hematologic Responses During First 3 Months of Treatment | Phase II - Dasatinib 140 mg + Decitabine 20 mg/m2 | 3 | Participants | ||
| Overall Survival | Phase I - Dasatinib 100 mg + Decitabine 10 mg/m2 | 12.0 | Full Range 0.6 to 36.8 | Months | |
| Overall Survival | Phase I - Dasatinib 100 mg + Decitabine 20 mg/m2 | 7.0 | Full Range 2.3 to 82.8 | Months | |
| Overall Survival | Phase I - Dasatinib 140 mg + Decitabine 10 mg/m2 | 57.8 | Full Range 0.9 to 79.4 | Months | |
| Overall Survival | Phase I - Dasatinib 140 mg + Decitabine 20 mg/m2 | 58.2 | Full Range 3.6 to 58.2 | Months | |
| Overall Survival | Phase II - Dasatinib 140 mg + Decitabine 10 mg/m2 | 62.0 | Full Range 6.0 to 62.0 | Months | |
| Overall Survival | Phase II - Dasatinib 140 mg + Decitabine 20 mg/m2 | 37.5 | Full Range 9.6 to 37.5 | Months | |
| Duration of Response | Phase I - Dasatinib 100 mg + Decitabine 10 mg/m2 | 36.8 | Full Range 1.2 to 36.8 | Months | |
| Duration of Response | Phase I - Dasatinib 100 mg + Decitabine 20 mg/m2 | 82 | Full Range 82 to 82 | Months | |
| Duration of Response | Phase I - Dasatinib 140 mg + Decitabine 10 mg/m2 | 57.8 | Full Range .09 to 79.4 | Months | |
| Duration of Response | Phase I - Dasatinib 140 mg + Decitabine 20 mg/m2 | 58 | Full Range 37 to 58 | Months |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT01498445/results